COMMUNIQUÉ RÉGLEMENTÉ
News
-
-
COMMUNIQUÉ RÉGLEMENTÉ
NFL BIOSCIENCES : RÉSULTATS DE L’ÉTUDE CESTO II
-
COMMUNIQUÉ RÉGLEMENTÉ
MEDESIS PHARMA: 2023 FULL-YEAR BUSINESS AND EARNINGS
-
-
-
-
COMMUNIQUÉ DE PRESSE
Affluent Medical annonce la mise à disposition d'un prospectus au titre de l'admission aux négociations de 6.190.831 actions émises dans le cadre d'une augmentation de capital avec suppression du DPS.
Affluent Medical annonce l'admission aux négociations de 6.190.831 actions nouvelles suite à une augmentation de capital avec suppression du DPS -
COMMUNIQUÉ DE PRESSE
Affluent Medical announces the availability of a prospectus for the admission to trading of 6,190,831 shares issued as part of a capital increase without preferential subscription rights.
Affluent Medical announces availability of a prospectus for trading of 6,190,831 shares in connection with a capital increase without preferential subscription rights. The AMF-approved Prospectus includes details of the Capital Increase -
COMMUNIQUÉ DE PRESSE
Affluent Medical announces the availability of a prospectus for the admission to trading of 6,190,831 shares issued as part of a capital increase without preferential subscription rights in favour of
Affluent Medical announces a capital increase without preferential subscription rights involving the trading of 6,190,831 shares. Edwards Lifesciences becomes a 9.21% shareholder after subscribing for €5 million. Risk factors are highlighted in the available prospectus -
